Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SciSparcSPRC -2.21%39 Earnings Yield (Joel Greenblatt) % is 454.55% as of Dec. 2025, which is 113% above its 10-year median of 213.36. GuruFocus rates SPRC with a GF Score™ of 39/100 and a GF Value™ of $3.03 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,343 Biotechnology companies, SciSparc ranks worse than 99.48% on this metric.
SciSparc's Enterprise Value for the quarter that ended in Dec. 2025 was $-2.82 Mil.
SciSparc's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-12.55 Mil. SciSparc's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 454.55%.
The historical rank and industry rank for SciSparc's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
SPRC'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -23090.74 Med: 213.36 Max: 23387.7
Current: -2500
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of SciSparc was 23387.70%. The lowest was -23090.74%. And the median was 213.36%.
SPRC's Earnings Yield (Joel Greenblatt) % is ranked worse than 99.48% of 1343
companies
in the Biotechnology industry
Industry Median: -9.63
vs SPRC: -2500.00
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. SciSparc's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
SciSparc Earnings Yield (Joel Greenblatt) % Related Terms
SciSparc Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for SciSparc's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SciSparc's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SciSparc Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SciSparc's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where SciSparc's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
SciSparcs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 454.55% mean?
SciSparc (SPRC) has a Earnings Yield (Joel Greenblatt) % of 454.55% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on SciSparc and its competitors. This is 113% above median its historical median of 213.36. According to the industry distribution chart, SciSparc ranks #1336 out of 1343 companies in the Biotechnology industry, placing it in the top 99.5%.
Is SciSparc's Earnings Yield (Joel Greenblatt) % too high?
SciSparc's current Earnings Yield (Joel Greenblatt) % of 454.55% is 113% above median its 10-year median of 213.36. Based on the distribution chart, SciSparc ranks #1336 out of 1343 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SciSparc has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does SciSparc's Earnings Yield (Joel Greenblatt) % compare to ACUT and ONCO?
According to the Biotechnology industry distribution chart, SciSparc ranks #1336 out of 1343 companies for Earnings Yield (Joel Greenblatt) %. This places SciSparc in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on SciSparc and its competitors. SciSparc's current Earnings Yield (Joel Greenblatt) % is 454.55%, which is 113% above median its own 10-year median of 213.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SciSparc stock overvalued right now?
Based on GuruFocus' analysis, SciSparc (SPRC) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.03, compared to a current price of $6.50 — trading 114.6% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 454.55%, which is 113% above median its 10-year median of 213.36. SciSparc's overall GF Score™ is 39/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For SciSparc (SPRC), the current Earnings Yield (Joel Greenblatt) % is 454.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SciSparc (SPRC) Overvalued in 2026?
Based on GuruFocus' analysis, SciSparc stock appears to be overvalued.
The current stock price of $6.50 is trading 114.6% above its estimated GF Value™ of $3.03.
GuruFocus considers SciSparc to be Significantly Overvalued.
Key valuation signals for SPRC:
Earnings Yield (Joel Greenblatt) %: 454.55% (113% above median its 10-year median of 213.36)
GF Value™: $3.03 vs. price of $6.50 (114.6% above fair value)
No single metric tells the full story. See the SPRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
39GF Score
Get the complete analysis for SPRC
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRC has been successfully added to your 
